Comparing the Roles of Antibodies to Nontyphoidal Salmonella enterica in High- and Low-Income Countries and Implications for Vaccine Development.

摘要

The article by Trebicka et al. (1) in the current issue of Clinical and Vaccine Immunology, on antibodies to Salmonella among adults and children in the United States, is paradoxically important for our understanding of immunity to nontyphoidal Salmonella (NTS) globally and the development of a much-needed vaccine for Africa. In recent years, there has been a growing awareness of the major public health problem attributable to NTS infections in sub-Saharan Africa (2–5). Unlike the self-limiting gastroenteritis commonly seen in high-income countries (6), the presentation in Africa is often with life-threatening invasive NTS (iNTS) disease (2, 3, 5). This usually manifests as bacteremia, where fever may be the only symptom, but also as meningitis (7).